An accompanying editorial describes the current regulatory process as “a thicket of special programs, flexible review criteria, and generous incentives,” and suggests starting points for reforms, including improving access to biosimilars.
An article published Tuesday in JAMA raises concerns that special and accelerated drug approval programs at the FDA in recent decades may have resulted in a process that approves drugs based on weaker data, without reducing overall drug development time.
An accompanying editorial describes the current regulatory process as “a thicket of special programs, flexible review criteria, and generous incentives,” and suggests starting points for reforms, including improving access to biosimilars.
In the article, Darrow et al. describe the evolution of FDA’s approach to drug approval from 1983 to 2018 based on federal laws, FDA regulations, drug approval records, and user fee records.
FDA must balance rigorous testing of new drugs to clearly define benefits and risks against timely approval for drug makers and access for patients. Special development, protection from generic competition, and expedited approval programs, such as Orphan Drug, Fast-Track, Accelerated Approval, Priority Review, and Breakthrough Therapy, were instituted by FDA to support drug development, especially for rare and serious diseases. However, in 2018, 81% of all new drugs won regulatory approval through one or more of the expedited programs, the article noted.
Special approval programs have increased administrative costs at FDA (paid for mostly by user fees), and postponements of generic competition have been costly to the US healthcare system, the authors noted.
Over the time period analyzed by the authors, FDA has accepted more surrogate measures, and as a result harder and more relevant clinical endpoints are studied less often. In 1995-1997, 80.6% of drug approvals were supported by at least 2 pivotal trials, compared to 52.8% in 2015-2017. The authors caution that reliance on surrogate measures may accelerate the approval of drugs that pose significant risk but have little clinical value.
The article reports that although FDA shortened its review times from more than 3 years in 1983 to less than 1 year in 2017, overall drug development time (from beginning human studies to approval) has not changed: approximately 8 years. The rate of new drug approvals (other than generics and biologics) has not increased substantially since 1983.
On the other hand, the authors acknowledge some positive outcomes. The median number of generics has increased following legislation to incentivize and accelerate generic drug development. Plus, biologic approvals are increasing over time, reflecting technological advancement. Although drugs are now supported by fewer studies before approval, the number of patients in these studies has not declined.
In the accompanying editorial, Joshua M. Sharfstein, MD, the former principal deputy commissioner of the FDA, suggests 4 starting points for reforms:
References
1. Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983-2018. JAMA. 2020;323(2):164-176. doi:10.1001/jama.2019.20288.
2. Sharfstein JM. Reform at the FDA—In need of reform. JAMA. 2020;323(2):123-124. doi:10.1001/jama.2019.20288.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.